Inventor · disambiguated record
Maxine Bauzon
Also filed as: BAUZON MAXINE
9 granted patents·19 pending applications·14 citations·filing 2006–2024
83Inventor score
Files withBAYER HEALTHCARE LLC6SCHERER TECHNOLOGIES LLC R P6COAGULANT THERAPEUTICS CORP5GLADIATOR BIOSCIENCES INC4SCHERING AG2
Top patents by PatentIndex Score
28 records- 0188US10894075B2Gla domains as targeting agentsGLADIATOR BIOSCIENCES INC·Filed 2014·Granted Jan 19, 2021·5 cites·14 claims
- 0287US10925926B2GLA domains as therapeutic agentsGLADIATOR BIOSCIENCES INC·Filed 2018·Granted Feb 23, 2021·2 cites·13 claims
- 0385US9694048B2Gla domains as targeting agentsBAYER HEALTHCARE LLC·Filed 2014·Granted Jul 4, 2017·6 cites·6 claims
- 0477US2023295596A1Short-acting factor vii polypeptidesCOAGULANT THERAPEUTICS CORP·Filed 2022·Application pending·0 cites
- 0576US10717970B2Short-acting factor VII polypeptidesCOAGULANT THERAPEUTICS CORP·Filed 2016·Granted Jul 21, 2020·1 cites·18 claims
- 0672US2025084182A1Antibody specific for mucin-1 and methods of use thereofSCHERER TECHNOLOGIES LLC R P·Filed 2024·Application pending·0 cites
- 0770US11530401B2Short-acting Factor VII polypeptidesCOAGULANT THERAPEUTICS CORP·Filed 2020·Granted Dec 20, 2022·0 cites·22 claims
- 0870US2021015900A1Gla domains as therapeutic agentsGLADIATOR BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 0966US11970546B2Antibody specific for Mucin-1 and methods of use thereofSCHERER TECHNOLOGIES LLC R P·Filed 2021·Granted Apr 30, 2024·0 cites·23 claims
- 1066US2025101098A1Antibodies and antibody conjugates specific for nectin-4 and methods of use thereofSCHERER TECHNOLOGIES LLC R P·Filed 2022·Application pending·0 cites
- 1165US2025121083A1Tumor-Associated Calcium Signal Transducer 2 (TACSTD2) Antibody-Maytansine Conjugates and Methods of Use ThereofSCHERER TECHNOLOGIES LLC R P·Filed 2022·Application pending·0 cites
- 1264US10273466B2Short-acting factor VII polypeptidesBAYER HEALTHCARE LLC·Filed 2014·Granted Apr 30, 2019·0 cites·14 claims
- 1360US2015344863A1Short-acting factor vii polypeptidesBAYER HEALTHCARE LLC·Filed 2013·Application pending·0 cites
- 1460US2025163183A1Camelid antibodies against activated protein c and uses thereofCOAGULANT THERAPEUTICS CORP·Filed 2023·Application pending·0 cites
- 1560US2017296624A1Gla domains as targeting agentsBAYER HEALTHCARE LLC·Filed 2017·Application pending·0 cites
- 1659US2025152724A1Antibody conjugates specific for mucin-1 and methods of use thereofSCHERER TECHNOLOGIES LLC R P·Filed 2022·Application pending·0 cites
- 1758US2024343818A1Antibodies Having Humanized Framework RegionsSCHERER TECHNOLOGIES LLC R P·Filed 2022·Application pending·0 cites
- 1857US8882484B2Methods and compositions for production of recombinant protein in HBX-expressing mammalian cellsJIN FANG·Filed 2009·Granted Nov 11, 2014·0 cites·13 claims
- 1957US2025188189A1Human antibodies against activated protein c and uses thereofCOAGULANT THERAPEUTICS CORP·Filed 2023·Application pending·0 cites
- 2057US2015044768A1Methods and compositions for production of recombinant protein in hbx-expressing mammalian cellsBAYER HEALTHCARE LLC·Filed 2014·Application pending·0 cites
- 2149US2011020925A1New modulating molecules for an improved regulated expression systemBAYER SCHERING PHARMA AG·Filed 2008·Application pending·0 cites
- 2245US2007179113A1GM-CSF gene therapy for Crohn's disease using an improved regulated expression systemSCHERING AKTIENGESELLACHAFT·Filed 2007·Application pending·0 cites
- 2344US11981723B2Method of targeting exosomesGLADIATOR BIOSCIENCES INC·Filed 2018·Granted May 14, 2024·0 cites·26 claims
- 2442US2008076729A1Interferon-beta gene therapy using an improved, regulated expression systemSCHERING AKTIENGESELLACHAFT·Filed 2007·Application pending·0 cites
- 2541US2015307625A1MONOCLONAL ANTIBODIES AGAINST ACTIVATED PROTEIN C (aPC)BAYER HEALTHCARE LLC·Filed 2013·Application pending·0 cites
- 2641US2006281703A1Treatment of disease using an improved regulated expression systemSCHERING AG·Filed 2006·Application pending·0 cites
- 2741US2006292609A1Interferon-beta gene therapy using an improved, regulated expression systemSCHERING AG·Filed 2006·Application pending·0 cites
- 2840US2012178693A1Cofactors for Thrombin Activation of Factor VII and Uses ThereofLIGHT DAVID·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Maxine Bauzon files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →